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Summary
Endovascular treatment of the thoracic aorta (TEVAR) is rapidly expanding, with new devices and techniques, combined with classical surgical
approaches in hybrid procedures. The present guidelines provide a standard format for reporting results of treatment in the thoracic aorta, and to
facilitate analysis of clinical results in various therapeutic approaches. These guidelines specify the essential information and definitions, which
should be provided in each article about TEVAR:
 Definitions of disease conditions
 Extent of the disease
 Comorbidities
 Exact demographics of the patient material
 Description of the procedure performed
 Devices which were utilized
 Methods for reporting early and late mortality, and morbidity
 Reinterventions and additional procedures
 Statistical evaluation
It is hoped that strict adherence to these criteria will make the future publications about TEVARmore comparable, and will enable the readership
to draw their own, scientifically validated conclusions about the reports.
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European Journal of Cardio-thoracic Surgery 35 (2009) 927—9301. Purpose
The purpose of these guidelines is to provide a standard
format for reporting results of treatment in the thoracic
aorta, and to facilitate analysis of clinical results in various
therapeutic approaches, so that meaningful conclusions can
be made and inferences drawn from investigations of
medical, surgical, and percutaneous interventional treat-* Corresponding author. Tel.: +41 44 2552229; fax: +41 44 2559270.
E-mail address: marko.turina@usz.ch (M.I. Turina).
1010-7940/$ — see front matter # 2008 European Association for Cardio-Thoracic
doi:10.1016/j.ejcts.2008.10.056ment of patients with various diseases of the thoracic aorta
[1,2].
2. Definition of disease conditions
Pathological entities that necessitate the treatment of
the thoracic aorta are numerous, and clinical presentations
are highly variable, reaching from asymptomatic dilatation of
the aorta to the life-threatening acute rupture with severe
hemodynamic compromise, necessitating an immediateSurgery. Published by Elsevier B.V. All rights reserved.
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tions can be found in the literature, and should be used [3].
Recently introduced term of ‘acute aortic syndrome’ [4]
encompasses a series of pathological conditions leading to an
acute presentation; nevertheless, for the purpose of exact
analysis of treatment results, a specific patho-anatomical
diagnosis should be given. Acuity of the disease process
(acute, subacute, and chronic) must be specified.
The following major diseases are encountered in the
descending aorta, and should be specified when reporting
results:
 aortic dissection, according to Svensson’s definition [5]
 degenerative aneurysm, chronic asymptomatic or sympto-
matic, as penetrating, ruptured, with or without compres-
sion symptoms
 intramural aortic hematoma
 aortic plaque, ruptured, embolizing, or asymptomatic
 Marfan and related connective tissue diseases (Ehlers-
Danlos syndrome, etc.)
 coarctation
 mycotic aneurysm.
 traumatic aneurysm (acute and late post-traumatic)
 aneurysm resulting from previous interventions on the
thoracic aorta (e.g. after coarctation repair, previous graft
replacement or EVAR treatment.
For administrative purposes, e.g. when reporting a unit’s
activity, a single, encompassing diagnosis of thoracic ‘aortic
aneurysm’ may be warranted. In scientific reports, individual
results in each of disease categories must be provided to
facilitate analysis of the results.
3. Extent of the disease
Many diseases of the thoracic aorta show a diffuse form,
frequently extending from the ascending aorta through the
aortic arch and descending thoracic aorta into the abdominal
aorta, and even into its branches. Exact definition of the
origin, extent and the termination of the dilatation should be
given, and patients categorized according to the location of
the disease process:
 ascending aorta (Stanford criteria can be used)
 aortic arch
 descending thoracic aorta. Crawford classification [6],
being universally accepted, should be used
 thoracoabdominal aorta
 abdominal aorta:
1. suprarenal
2. juxtarenal
3. infrarenal
Disease process can (and frequently does) encompass
several locations in a single patient.
4. Clinical classification
Aneurysm should be classified according to its clinical
presentationas symptomaticorasymptomatic.Symptomaticaneurysm is classified as acute (within 2 weeks after onset of
symptoms)andchronic.Furthermore,thelocalcomplications
oftheaneurysm(compressionorerosionofadjacentstructures,
thrombosis,embolization,containedorfreerupture)shouldbe
mentioned. Hemodynamic condition at the presentation
(stable, with or without preceding resuscitation; shock,
unstable)mustbenoted.
5. Comorbidities
Scientific analysis of the results necessitates an exact
definition of patient characteristics. Diseases of the
thoracic aorta are, for the most part, encountered in
patients of advanced age with multiple comorbidities,
which often dictate the choice of treatment. The
preoperative presence of these conditions should be
identified according to standard definitions: renal insuffi-
ciency, renal failure (dialysis dependent, acute preopera-
tive or chronic), COPD, peripheral vascular disease,
neurovascular involvement, diabetes (insulin dependent
or non-insulin dependent), previous neurological events
(stroke, TIA, spinal chord ischemia, etc.), coronary artery
disease, previous surgical interventions (e.g. CABG, AAA)
etc. Use of standard risk assessment scores (e.g. additive
EuroSCORE) is suggested to permit comparison between
various studies.
6. Demographics
Exact definition of patient cohort should be given:
age (mean  SD), gender, previous surgeries or interven-
tions, time since diagnosis, comorbidities (see above).
Selection of patients for a particular modality of treat-
ment, i.e. conservative versus open versus endovascular,
exerts the major influence on the results. In all series, the
statement about the total cohort from which a
particular patient population was being selected should
be given (including the total number of patients from
whom this selected patient population was drawn, along
with the year horizon over which the patients were chosen)
to assess the magnitude of pretreatment selection.
Delineation of patient selection criteria, and how the
criteria have changed over time should be provided.
Furthermore, the patient series should be consecutive, i.e.
include all patients which have been subjected to a
particular treatment method within the specified time
frame. In all reports, the results must be analyzed with
‘intention to treat’ method, which should be documented
at the start of the trial (‘time zero’). Later crossovers
should be documented, with the reason for abandoning
originally chosen treatment, and their eventual clinical
outcome.
The study design and methodology must be explicitly
defined in the study or report. Duplicated studies reporting
different outcomes but with the same patient groups must be
clarified. This is important for cumulative evidence to be
properly assessed for systematic review and meta-analysis in
RCT, nRCT and case series for practice guidelines recom-
mendations [7,8].
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Some pathological conditions of the descending aorta
display very slow progression, and the extended follow-up (at
least 1—2 years) is essential when comparing various
treatment modalities to the conservative management
(medical therapy or ‘watch and wait’). Patient’s condition
at the time of follow-up with respect to the aneurysm
(survival; complication-free and rupture-free survival; free-
dom from expansion or endoleak; additional interventions)
should be mentioned. Exact method of follow-up must be
specified (letter to the patient, telephone contact, informa-
tion from the attending physician, access to the national
death registry or information from major insurance carriers
such as Medicare, etc. Furthermore, imaging modalities (CT,
MRI, echo, angiography, etc.) should be described. The mode
of follow-up should be included, whether prospective
anniversary contact (although periodic follow-up may be
at intervals shorter or longer than one year); or cross-
sectional (at a common closing date), whereby an entire
group of patients is followed more-or-less at the same
calendar time, despite their index procedures occurring at
widely disparate times. Prospective follow-up is preferred to
retrospective follow-up. The extent of follow-up should be
reported, and should be at least 95% complete. Extent of loss
to follow-up must be clearly delineated so that the
denominator is known at all reported time points. Ascertain-
ment of complete data for losses to follow-up should be
applied with just as much effort for prospective analyses as
for retrospective analyses, since the latter are particularly
prone to survivor bias (i.e., selective follow-up of survivors or
those who are able to present for follow-up clinical will lead
to a bias toward reporting on the healthiest cohort, and will
preferentially ignore those who have died or are too severely
incapacitated for follow-up clinics).
Cumulative event rates should be reported rather than
event rates within discrete intervals. Ideally, time to event
will be reported over the duration of follow-up, as well as
proportion of patients with an event at discrete endpoints
(specifying the numerator and denominator).
The number of patients experiencing an outcome once or
more should be reported, even for events that may occur
repeatedly within the same patient (such as stroke,
endoleak, need for reintervention). If the author also wishes
to provide the total number of events (i.e., allowing for more
than one event per patient to be counted), the rate per
patient-years may be provided.
8. Procedure performed
In diseases of thoracic aorta, there is a choice between
conservativeand invasive treatment.This latter group involves
classical open surgical repair (OPEN), endovascular mode
(EVAR, or better TEVAR), and a combination thereof, often
referred to as hybrid procedure. The treatment modalities
should be clearly stated in the ‘Methods’ section of the report;
any crossovers should be mentioned, with their respective
timing (whichprocedurefirst). ‘Intention-to-treat’ description
should be applied, and all deviations and the reasons for the
abandonment of the original intention should be given.9. Devices used
There is already a large choice of endovascular devices,
especially outside of the U.S., and new techniques and
endografts are expected to appear in near future. It is
essential to describe in detail the devices and grafts which
have been used in the report, along with the manufacturer’s
name and address, and indicate if the device is available for
general use, or if it is only an experimental model.
As access is an essential element of most endovascular and
some open procedures it is important to describe the type
and diameter of access sheaths, cannulae that were used and
which artery was accessed and its diameter e.g. common
femoral/iliac/axillary, 9, 10, 12 mm.
It is also necessary to describe the number and length of
devices used as well as the size/diameter of the device and
its ratio to the aortic wall diameter. The landing zone, its
length, and any major arterial branch that is covered as well
as any extra-anatomic bypass performed.
10. Early mortality and morbidity (endpoints of the
study)
All-cause mortality should be reported, rather than only
vascular or cardiac mortality; although, causes of death may
also be specified. Early mortality will be reported as all-cause
mortality at 30 and 90 days. Preferably, longer term follow-
up should also be provided at 6 months, 1 year, 2 years, 5
years, and 10 years and should be depicted by actuarial
estimates (with number remaining at risk and confidence
intervals) or as simple percentages, regardless the patient’s
location, be it home or in a healthcare facility. Mortality
should always be reported as the cumulative mortality (i.e.,
all deaths occurring in hospital should be included within the
reported 30-day mortality, and all 30-day deaths should be
accumulated within the 1 year mortality, etc.). All complica-
tions of the chosen treatment will be documented at the
same time interval, and categorized as:
 disease related
 procedure related
 device related
 others (e.g. atrial fibrillation, etc.)
Reporting should be mandatory, and the complication
and/or lack thereof, always mentioned for:
 access complication (report separately for complications
during initial access attempt, and complications post-
operatively such as significant bleeding, hematoma,
wound infection)
 ischemic complications (peripheral and visceral), reported
in aggregate, and individually for all types observed, such
as gut ischemia, limb ischemia
 stroke and neurological morbidity [9]; define CVA, TIA,
paraplegia, etc.
 renal failure (defined as new onset need for renal
replacement therapy)
 renal dysfunction (serum creatinin increase of >50% of
baseline)
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vated cardiac enzyme, new Q wave, etc.)
 reoperations or repeat procedures
 patients transfused
 major blood loss, defined as any episode of major internal
or external bleeding that causes death, hospitalization or
permanent injury or necessitates transfusion)
 duration of intubation
 length of ICU and hospital stay
 infection (specify pneumonia, wound, sepsis)
 endoleak, classified as type I—IV, according to accepted
criteria [10]
 endocarditis; furthermore, imaging modalities (CT, MRI,
echo, angiography, etc.) should be described.
 arrhythmias
11. Hybrid procedures
If a hybrid procedure is used, this method of treatment
should be described in detail. In particular, the type of the
procedures (surgical and endovascular); the sequence of
interventions; time between two (or more) interventions;
the vessels approached; the imagining before, during and
after the intervention; drug regimen in the interval, should
be described.
12. Reinterventions and additional procedures
Need for aortic reintervention should be reported, and
defined as any surgical or percutaneous interventional
catheter procedure that repairs, otherwise alters or adjusts,
or replaces a previously implanted prosthesis or repaired
aorta. In addition to surgical reoperations, balloon dilata-
tion, interventional manipulation, embolization, reposition-
ing, or retrieval, and other catheter-based interventions forprosthesis-related complications are also considered rein-
terventions. Need for access site reintervention should also
be reported. Indications for reintervention must be reported.
Open surgical and percutaneous catheter reinterventions
should be listed separately.
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